Live Quote · OTCARNIHealthcare· Biotechnology

Arno Therapeutics, Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
36/100
Weak
60
Valuation
40
Profitability
15
Growth
36
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARNI research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$0.00
Company Overviewwww.arnothera.com

About the company

Arno Therapeutics, Inc. , headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials.

CEO
David M. Tanen
IPO
2008
Employees
4
HQ
Flemington, NJ, US

Price Chart

+0.00% · this period
$0.00$0.00$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$4.93K
P/E
-0.00
P/S
0.00
P/B
-0.00
EV/EBITDA
-0.15
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
250.44%
ROIC
755.35%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-11,536,366 · -248.46%
EPS
$-0.57 · -250.00%
Op Income
$-13,411,811
FCF YoY
47.06%
Performance & Tape
52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
1.55
Avg Volume
39

Get TickerSpark's AI analysis on ARNI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jan 25, 13Kariv Tomerother0
Jan 25, 13Kariv Tomerother0
Jan 25, 13Kariv Tomerother0
Aug 15, 16Belldegrun Ariebuy714,285
Aug 15, 16Belldegrun Ariebuy357,142
Aug 15, 16Kariv Tomerbuy349,168
Aug 15, 16Kariv Tomerbuy263,017
Aug 15, 16Kariv Tomerbuy102,100
Aug 15, 16Kariv Tomerbuy174,584
Aug 15, 16Kariv Tomerbuy131,508
Coverage · ARNI

Our ARNI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ARNI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ARNI report →
Internal Compare

Similar companies

Peers in the same neighborhood.